Metabolic abnormalities in patients with HIV infection.
I would like to focus on metabolic alterations, and the problems associated with them such as dyslipidemia, insulin resistance, fat loss or lipoatrophy, and fat accumulation. There are also conditions such as bone disease, hyperlactatemia, and other complications. It is not clear whether these problems are just toxicities of the drugs, how they are related to HIV independent of treatments, and whether they belong in discussions of metabolic complications. For the purposes of this discussion, I would like to consider each problem individually while also recognizing overlapping elements in an effort to understand complex etiologic interrelationships.
Mulligan
Kathleen
K
University of California, San Francisco, Division of Endocrinology, San Francisco General Hospital, California, USA. kmulligan@sfghgcrc.ucsf.edu
D000140:Acidosis, Lactic / Q000209:etiology* / Q000503:physiopathology; D019380:Anti-HIV Agents / Q000009:adverse effects* / Q000627:therapeutic use; D001823:Body Composition; D044882:Glucose Metabolism Disorders / Q000209:etiology* / Q000503:physiopathology; D015658:HIV Infections / Q000150:complications / Q000188:drug therapy / Q000503:physiopathology*; D006801:Humans; D006949:Hyperlipidemias / Q000209:etiology* / Q000503:physiopathology; D007333:Insulin Resistance; D008060:Lipodystrophy / Q000209:etiology* / Q000503:physiopathology
D019380:Anti-HIV Agents